Promising Early Results with New Vaccine from China in Phase I Trial

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial – The Lancet

Commentaries: First human trial of COVID-19 vaccine finds it is safe and induces rapid immune response – The Lancet AND Early Study Of Covid-19 Vaccine Developed In China Sees Mixed Results – Forbes AND Coronavirus Vaccine Shows Promising Early Results in China – The New York Times AND A Chinese biotech just published the first human data for its coronavirus vaccine candidate, supporting further trials – Business Insider AND Experts skeptical after researchers report positive vaccine results – CNN AND Two COVID-19 Vaccine Candidates Induce Immune Response In Healthy Volunteers – Health Policy Watch